Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous